Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Pamela Joy Hodul

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2004-2702; OpenAlex author ID A5112117376. Sources: ClinicalTrials.gov.

Their work

Papers
44 (first author 0, last author 6)
Trials
6 (principal investigator on 6)
Grants
0
Labs led
1
Collaborators
77
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: 5 papers · 2016: 4 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 5 papers, 2 trials · 2023: 3 papers, 2 trials · 2024: 4 papers, 2 trials · 2025: 6 papers · 2026: 3 papers

Papers 44

  1. Depression as a potential early indicator of pancreatic cancer: a systematic review of prevalence, mechanisms, and temporal associations. Co-author DOI 10.1080/07347332.2026.2679587↗
  2. A patient-mediated strategy to improve nutrition care after transition from hospital to home for pancreatic cancer surgery: a pilot randomised controlled trial… Last author DOI 10.1136/bmjopen-2025-113207↗
  3. Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment. Co-author DOI 10.1200/po-25-00807↗
  4. Early Supportive and Nutritional Care For Adults With Pancreatic Cancer: A Pilot Study. Last author DOI 10.1016/j.jpainsymman.2025.07.032↗
  5. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  6. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  7. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  8. Influence of Coping, Esteem, and Resilience on Caregiver Distress in Pancreatic Cancer Patient-Caregiver Dyads. Last author DOI 10.3390/healthcare13020114↗
  9. Personalizing Patient Education for Pancreatic Cancer Patients Receiving Multidisciplinary Care with Integration of Novel Digital Tools. Co-author DOI 10.3390/healthcare13151929↗
  10. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A st… Last author DOI 10.1016/j.conctc.2024.101271↗
  11. Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.28556↗
  12. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  13. The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm13226800↗
  14. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Co-author DOI 10.1016/j.sopen.2023.02.001↗
  15. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… Co-author DOI 10.1177/10732748221150228↗
  16. Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.28508↗
  17. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Co-author DOI 10.1007/s00464-021-08845-9↗
  18. Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being. Last author DOI 10.1007/s10865-022-00354-x↗
  19. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. Co-author DOI 10.1007/s11605-021-05130-x↗
  20. A Path Forward for Understanding and Addressing Multifaceted Pancreatic Cancer Disparities. Last author DOI 10.1053/j.gastro.2022.04.047↗
  21. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Co-author DOI 10.1097/as9.0000000000000197↗
  22. The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis. Co-author DOI 10.1097/sla.0000000000003706↗
  23. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  24. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. Co-author DOI 10.1002/jso.26103↗
  25. Completion of adjuvant therapy in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.07.008↗
  26. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pa… Co-author DOI 10.1186/s12885-020-07182-9↗
  27. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor … Co-author DOI 10.1002/cam4.2180↗
  28. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.21037/jgo.2017.09.13↗
  29. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy… Co-author DOI 10.1080/0284186x.2016.1256497↗
  30. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.21037/jgo.2017.08.05↗
  31. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal… Co-author DOI 10.1016/j.surg.2016.04.039↗
  32. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-015-5006-1↗
  33. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy co… Co-author DOI 10.21037/jgo.2016.03.15↗
  34. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2015.075↗
  35. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Co-author DOI 10.1007/s00464-015-4075-3↗
  36. Resected pancreatic cancer outcomes in the elderly. Co-author DOI 10.1016/j.jgo.2014.11.005↗
  37. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Co-author DOI 10.1097/rlu.0000000000000837↗
  38. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarc… Co-author DOI 10.3109/0284186x.2015.1004367↗
  39. Outcomes of resected pancreatic cancer in patients age ≥70. Co-author DOI 10.3978/j.issn.2078-6891.2015.038↗
  40. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.1002/cncr.28543↗
  41. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Co-author DOI 10.1016/j.ijrobp.2013.02.022↗
  42. Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. Co-author DOI 10.1371/journal.pone.0052526↗
  43. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. Co-author DOI 10.1002/jso.21954↗
  44. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Co-author PMID 22368736↗

Trials 6

  1. Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study Principal investigator NCT06323291↗
  2. Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer Principal investigator NCT06423963↗
  3. Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS) Principal investigator NCT06001268↗
  4. The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response Principal investigator NCT06050395↗
  5. Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer Principal investigator NCT05438927↗
  6. Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients Principal investigator NCT05675059↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mokenge Peter Malafa · 34 shared papers, 2011–2026 · strength 3.52
  2. A. Alishani Tabriz · 4 shared papers, 3 shared trials, 2022–2026 · strength 2.60
  3. Jason B. Fleming · 16 shared papers, 2019–2025 · strength 2.30
  4. Sarah E. Hoffe · 22 shared papers, 2011–2026 · strength 2.19
  5. Jennifer B. Permuth · 11 shared papers, 2019–2026 · strength 1.83
  6. Jason W. Denbo · 11 shared papers, 2020–2025 · strength 1.80
  7. José M. Pimiento · 13 shared papers, 2013–2025 · strength 1.52
  8. Kea L. Turner · 4 shared papers, 1 shared trial, 2023–2026 · strength 1.51
  9. Nicole Nardella · 7 shared papers, 2024–2026 · strength 1.51
  10. Jessica M. Frakes · 12 shared papers, 2015–2025 · strength 1.36
  11. Nathan H. Parker · 3 shared papers, 1 shared trial, 2024–2025 · strength 1.15
  12. Benjamin Daniel Powers · 8 shared papers, 2019–2023 · strength 1.07
  13. Dae Won Kim · 6 shared papers, 2022–2026 · strength 1.05
  14. Sylvia L. Crowder · 2 shared papers, 1 shared trial, 2023–2025 · strength 0.89
  15. Dae Won Kim · 5 shared papers, 2022–2025 · strength 0.87
  16. Gregory M. Springett · 14 shared papers, 2011–2017 · strength 0.68
  17. Ravi Shridhar · 12 shared papers, 2011–2017 · strength 0.60
  18. Daniel A. Anaya · 4 shared papers, 2021–2023 · strength 0.56
  19. Kelvin Allenson · 3 shared papers, 2022–2025 · strength 0.55
  20. Yu Chen Lin · 2 shared papers, 2025–2026 · strength 0.48
  21. Eric A. Mellon · 8 shared papers, 2013–2018 · strength 0.46
  22. Dung‐Tsa Chen · 5 shared papers, 2013–2025 · strength 0.46
  23. Richard D. Kim · 3 shared papers, 2015–2026 · strength 0.45
  24. Kenneth Lee Meredith · 6 shared papers, 2013–2025 · strength 0.40
  25. Brent Taiting Xia · 2 shared papers, 2022–2025 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.